United States

Cancer Treatment Centers of America names Maurie Markman president

Thursday, May 29, 2014 01:39 PM

Cancer Treatment Centers of America (CTCA), a national network of five hospitals that specialize in the treatment of patients fighting complex or advanced-stage cancer, has appointed Maurie Markman, M.D., president of the company's Medicine & Science unit, where he will be responsible for advancing the organization's overall commitment to clinical excellence, innovation, safety and patient satisfaction. Markman was senior vice president of Clinical Affairs and national director of Medical Oncology at CTCA.

More... »

WIRB Copernicus Group

NIA/NIH grants $1.4M to Cognition Therapeutics' Alzheimer's program

Friday, May 23, 2014 02:35 PM

Cognition Therapeutics, an innovative research and drug discovery organization focused on the development of novel disease-modifying therapeutics for neurodegenerative diseases, has announced that its small molecule soluble Abeta receptor antagonist program for the treatment of Alzheimer's disease (AD) has been selected for funding by the National Institute on Aging (NIA)/NIH Alzheimer's Disease Drug Development Program. This cooperative agreement program for Alzheimer's disease translational research will provide Cognition Therapeutics with an estimated $1.4M in funding over four years to support critical drug development activities aimed at securing IND status for the company's first-in-class therapeutics.

More... »

CRF Health eCOA webinar series

Jack Modell joins Rho as senior medical officer

Thursday, May 22, 2014 11:15 AM

Rho, a privately held CRO located in Chapel Hill, N.C., has announced that Dr. Jack Modell joined its team as senior medical officer, bringing 20 years of experience in clinical research, teaching and patient care in academic medicine, and an additional 10 years of experience in clinical drug development (phase II-IV), medical affairs, medical governance, drug safety and management within the pharmaceutical industry. 

More... »

Inhibikase Therapeutics receives Orphan Drug Designation for PML

Thursday, May 22, 2014 11:08 AM

Inhibikase Therapeutics, a developer of products to treat infectious diseases with little or no resistance, has received Orphan Drug Designation for imatinib to treat progressive multifocal leukoencephalopathy (PML) from the FDA.

More... »

Report: Value of U.S. health services M&A deals up 152%

Wednesday, May 21, 2014 01:29 PM

U.S. health services M&A total deal value rose 152% to $12.3 billion during the first quarter of 2014 compared to the same period in 2013, according to an analysis of M&A trends and outlook for the health services sector issued by PricewaterhouseCoopers U.S.

More... »

PDS launches first publicly available, FDA-validated dataset for SEND

Wednesday, May 21, 2014 01:28 PM

PDS, a global provider of intuitive data management software and solutions for life sciences research, has made an FDA-validated, preclinical research SEND dataset available to the public free of charge and qualification.

More... »

Kymab receives $40M investment from Wellcome Trust, Gates Foundation

Monday, May 19, 2014 01:25 PM

The Bill & Melinda Gates Foundation and the Wellcome Trust each invested $20 million in Kymab, a monoclonal antibody biopharmaceutical company, to enable Kymab to maximize its Kymouse platform and advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies in areas of significant unmet medical need, including cancer and inflammation.

More... »

SAFE-BioPharma added to worldwide Adobe Approved Trust List

Friday, May 16, 2014 11:32 AM

Adobe has added SAFE-BioPharma to its Adobe Approved Trust List (AATL). Effective immediately, anyone with a SAFE-BioPharma identity credential will be able to sign a PDF document in Adobe Acrobat, or Reader that will be automatically trusted globally by any other user of Adobe Acrobat, or Reader.

More... »

Janssen Labs expands to San Francisco, adds three to @LabCentral

Thursday, May 15, 2014 01:26 PM

Janssen Labs, part of Janssen R&D, plans to open Janssen Labs @South San Francisco, a new 30,000-square-foot, standalone operation based in South San Francisco, Calif. The new location will accommodate up to 50 independent, emerging companies to be co-located with staff from Johnson & Johnson Innovation. Like the flagship Janssen Labs in San Diego, Janssen Labs @South San Francisco will include a combination of shared and private lab and office spaces and feature value-added solutions including operational support, education and business services. Janssen Labs @South San Francisco is scheduled to open at the end of the year.

More... »

Pernix to acquire Treximet migraine tablets from GlaxoSmithKline

Thursday, May 15, 2014 11:23 AM

Pernix Therapeutics, a specialty pharmaceutical company, has signed an agreement with GlaxoSmithKline to acquire the U.S. rights to Treximet (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs